Shares of Durata Therapeutics rose as much as 3.6% on 27 September on the news the company is seeking the FDA's approval to market dalbavancin as a treatment for patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive microorganisms, including methicillin resistant Staphylococcus aureus (MRSA).
The stock closed at $9.10, a gain of 21 cents, or 2.36%.